Free Newsletter
Pfizer seeks dismissal of Nigeria lawsuit
Pfizer has unveiled its defense in the Nigerian lawsuit over a clinical trial that allegedly killed 11 children and injured 189 others during a meningitis epidemic. The company says it actually saved lives by administering the experimental antibiotic Trovan. The children who died were victims of the disease itself, not the drug, the court filing states. Pfizer is asking the Nigerian court to throw out the lawsuits altogether.
Trovan has a checkered history: Initially a popular antibiotic in the U.S. and Europe, it was eventually severely restricted (in the States) or banned (in the EU). In the U.S., it was never approved by regulators for use in children. Filed in May, these four lawsuits charge that Pfizer didn't tell the sick children's families that they were participating in a trial. Nigeria is seeking $8.5 billion in penalties, plus pursuing criminal charges against the company and its executives and agents.
- see this article for more
Related Articles:
Trial deaths spur criminal charges against Pfizer. Report
Pfizer 'exploited' children in African trial. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: